Medical Condition News

RSS

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

Green tea could modulate smoke-induced lung cancer

Drinking green tea could modulate the effect of smoking on lung cancer. Results of this hospital-based, randomized study conducted in Taiwan were presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held here from Jan. 11-14, 2010.

13 Jan 2010

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

LUMEN 2010 analyzes strategies to reduce rising mortality in women with cardiovascular disease

It is no longer a theory. Percutaneous coronary intervention (PCI) or coronary angioplasty is the best treatment for a person presenting with STEMI (ST- elevation myocardial infarction), a heart attack caused by complete obstruction of a coronary artery.

13 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

Studies show naturally-occurring protein in humans restores motor function in rats after a stroke

People with impaired mobility after a stroke soon may have a therapy that restores limb function long after the injury, if a supplemental protein works as well in humans as it does in paralyzed rats.

13 Jan 2010

Research reveals how cancers shield themselves from immune attack

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site.

13 Jan 2010

Blood test may be effective for diagnosing lung cancer

Of the nearly 150,000 abnormal chest X-rays performed each year in the United States, 25 percent of patients will display only benign lung pathologies on further surgical examination.

13 Jan 2010

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.

13 Jan 2010

Karolinska Institutet receives donation to advance breast cancer research

"We are very happy to be donating money to the fight against breast cancer, especially in light of our own family history," says M-rit Rausing. "Hans's mother and grandmother both died of the disease, and his father, Ruben, put considerable effort into finding a cure. Of course, it's also important when you think that breast cancer is one of the most common diseases."

13 Jan 2010

BDSI to discuss planned BEMA Granisetron IND with the FDA

BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI’s antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.

13 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

13 Jan 2010

Scientists identify fast-acting compound to improve cognitive function impairments

A fast-acting compound that appears to improve cognitive function impairments in mice similar to those found in patients with progressive Alzheimer's disease has been identified by scientists at Wake Forest University School of Medicine and the Vanderbilt University Medical Center Program in Drug Discovery.

13 Jan 2010

Caffeine abstinence: An ineffective and potentially distressing tinnitus therapy

New research has found giving up caffeine does not relieve tinnitus and acute caffeine withdrawal might add to the problem. This is the first study of its kind to look at the effect of caffeine consumption on tinnitus.

13 Jan 2010

AARDA pleased with FDA's approval of RA drug ACTEMRA

Friday, January 8, 2010, the Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab), a new biologic response modifier for adult patients with moderately to severely active rheumatoid arthritis (RA).

13 Jan 2010

Research suggests variation of CETP gene is linked to lowered risk of dementia and AD

Preliminary research suggests that variation of a gene for a plasma protein is associated with slower age-related memory decline and a lower risk of dementia and Alzheimer disease (AD), according to a study in the January 13 issue of JAMA.

13 Jan 2010

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus.

12 Jan 2010

Scientists go beyond single-gene models to probe inborn heart defects

Studying genes that regulate early heart development in animals, scientists have solved a puzzle about one gene's role, finding that it acts in concert with a related gene. Their finding contributes to understanding how the earliest stages of heart development may go awry, resulting in congenital heart defects in humans.

12 Jan 2010

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary objective for the Phase III part of this study is to determine if Onrigin™ plus LDAC improves overall survival compared with LDAC alone.

12 Jan 2010

Medical Condition News

First sulfite-free rectal suspension for UC

Green tea could modulate smoke-induced lung cancer

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

LUMEN 2010 analyzes strategies to reduce rising mortality in women with cardiovascular disease

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Studies show naturally-occurring protein in humans restores motor function in rats after a stroke

Research reveals how cancers shield themselves from immune attack

Blood test may be effective for diagnosing lung cancer

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Karolinska Institutet receives donation to advance breast cancer research

BDSI to discuss planned BEMA Granisetron IND with the FDA

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Scientists identify fast-acting compound to improve cognitive function impairments

Caffeine abstinence: An ineffective and potentially distressing tinnitus therapy

AARDA pleased with FDA's approval of RA drug ACTEMRA

Research suggests variation of CETP gene is linked to lowered risk of dementia and AD

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Scientists go beyond single-gene models to probe inborn heart defects

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Latest News